Mechanisms of the activated TME that can induce therapy resistance include promotion of pro-survival pathways, stemness traits, and/or metabolic reprogramming; CAFs can regulate each of these mechanisms to induce endocrine resistance in ER+ breast cancer cells. The gene discussed is ESR1; the disease is breast carcinoma.